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Proteolytic Activation of Matrix Metalloproteinase-9
in Skin Wound Healing Is Inhibited by
a-1-Antichymotrypsin
Yuan-Ping Han1,2, Chunli Yan1 and Warren L. Garner1
An excessive amount of matrix metalloproteinase-9 (MMP-9) has been well documented in inflammatory
diseases, including chronic wounds and cancers. Secreted as a zymogen, proMMP-9 can be irreversibly
converted to a mature form through cleavage of the N-terminal propeptide domain. Although the converting
enzyme for proMMP-9 in human tissues is unknown, we previously found that tumor necrosis factor-a (TNF-a)
promotes activation of proMMP-9 in human skin, and characterized the converting activities as tissue-
associated chymotrypsin-like proteinases. On the other hand, the pathophysiologic inhibitor to prevent
proMMP-9 maturation also remains elusive. In this regard, we observed the presence of the inhibitory property
in burn blister fluid that abrogates the skin extract–mediated activation of proMMP-9. Then we determined that
a-1-antichymotrypsin (a-ACT), an acute-phase factor abundantly present in the blister, effectively inhibited
proMMP-9 activation in human and rodent skin. In contrast, the aminophenylmercuric acetate-induced
‘‘cysteine switch’’ and activation of proMMP-9 were not affected by a-ACT. TNF-a-induced activation of proMMP-9
by the explants of human skin was inhibited by a-ACT but not by related a-1-antitrypsin. a-ACT specifically
attenuated maturation of proMMP-9 but not proMMP-2 or proMMP-13. Furthermore, short peptides that mimic
the reactive center loop (RCL) of a-ACT were sufficient to inhibit the conversion. Mutation analysis
demonstrated that a conserved leucine within the RCL was critical for a-ACT-exerted inhibition. In chronic
wounds, a large amount of mature MMP-9 was associated with fragmentation and inactivation of a-ACT. Taken
together, these results demonstrate that, to the best of our knowledge, a-ACT is a previously unreported
pathophysiologic inhibitor that controls proMMP-9 activation in skin tissue.
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INTRODUCTION
Large-scale remodeling of the extracellular matrix occurs
in embryonic development and recedes to a minimal level
in adult tissues to maintain tissue homeostasis (Werb, 1997).
Tissue remodeling is regulated by proteinases and their
inhibitors at the level of expression, deposition, activation,
and inhibition (Birkedal-Hansen, 1995; Parks, 1999). In many
inflammation-associated diseases, such as chronic wounds
and cancers, proteinases are predominantly expressed, which
activates quiescent cells, promotes cell migration, and
triggers cell differentiation (Han, 2006). Matrix metallo-
proteinase-9 (MMP-9), previously called gelatinase B, is
believed to function in the remodeling of the basement
membrane zone because several extracellular matrix proteins
in the basement membrane zone, such as type IV collagen
and BP180, have been identified as the substrates for this
proteinase (Seltzer et al., 1989; Stahle-Backdahl et al., 1994).
Nascent proMMP-9 (92 kDa in human) is a zymogen that
remains latent through the interaction between a conserved
cysteine within the N-terminal propeptide domain and a zinc
ion within the catalytic domain. The activation of proMMP by
disruption of the cysteine–zinc bond is executed mainly by
cleavage of the propeptide domain of B100 amino-acid
residues, which consequently leads to reorganization of the
cysteine interactions and conformation changes, a process
called ‘‘cysteine switch’’ (Springman et al., 1990). In early
development and tissue injury, proMMP-9 is transiently
expressed and then declines as tissue remodeling proceeds
(Salo et al., 1994; Young and Grinnell, 1994; Moses et al.,
1996; Tarlton et al., 1997). However, in prolonged inflam-
mation, proMMP-9 is readily converted into the active or
mature form (82 kDa) (Wysocki et al., 1993; Weckroth et al.,
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1996; Yager et al., 1996; Han et al., 2001b; Ladwig et al.,
2002). Excessive and prolonged expression and activation of
MMPs are etiologic causes of chronic diseases due, at least in
part, to excessive tissue destruction (Trengove et al., 1999;
Warner et al., 2001).
The mechanism of proMMP-9 activation in human
diseases is currently unknown. Isolated human skin cells
such as keratinocytes or dermal fibroblasts can secrete
proMMP-9 in response to defined cytokine stimulation;
however, the activation of proMMP-9 is rarely reconstituted
in pure cell cultures (Oikarinen et al., 1993; Han et al.,
2001b). The failure of proMMP-9 activation in cell cultures is
likely due to the lack of ‘‘tissue milieu,’’ the interaction
among cells, cytokines, and extracellular matrix. In this
regard, we successfully reconstituted the activation of
proMMP-9 through organ culture of human skin treated with
specific cytokines (Han et al., 2001a). Through this approach,
we have found that transforming growth factor-b (TGF-b)
promotes expression of proMMP-9, whereas tumor necrosis
factor-a (TNF-a) exerts maturation of the zymogen by
explants of human skin. Furthermore, we characterized the
converting factor in human skin as a tissue-associated
chymotrypsin-like proteinase (Han et al., 2002). Based on
such findings, we searched for physiologic or pathologic
inhibitors that control proMMP-9 activation in human skin.
First, we found that the TNF-a-mediated activation of
proMMP-9 in human skin is sufficiently regulated through
downregulation of tissue inhibitor of metalloproteinase 1
(TIMP-1), a tissue inhibitor binding to proMMP-9 and
preventing the zymogen from access to the converting
enzyme. Then we embarked on a search for the patho-
physiologic inhibitor antagonizing the conversion per se.
Initially, we noticed the presence of inhibitory factor(s) in
thermal burn blister fluid, which prevents the proteolytic
processing of proMMP-9. This finding indicates that the
inhibitor may be an acute-phase factor produced in response
to trauma. Given the inhibition of proMMP-9 activation
by N-tosyl-phenylalanyl-chloromethyl ketone (TPCK) and
chymostatin, two specific inhibitors of chymotrypsin (Han
et al., 2002, 2005), we speculated on the presence of an
equivalent pathophysiologic inhibitor. We then examined
whether the acute-phase factor(s) had antichymotrypsin
activity. Among them, we noticed a-1-antichymotrypsin
(a-ACT), an acute-phase factor produced in the liver in
response to trauma. This led us to examine a-ACT for its
inhibition of proMMP-9 conversion in human and rodent
skin. Indeed, a-ACT potently inhibits the TNF-a-induced
conversion of proMMP-9 in explants of human skin. More-
over, we found that a-ACT, but not MMP inhibitor, also
inhibits proMMP-9 activation in rat skin; conversely, IL-1-
induced activation of proMMP-9 in rat hepatic stellate cells is
refractory to a-ACT but is antagonized by MMP inhibitor
(Han et al., 2007). Thus, activation of proMMP-9 appears
to be controlled by tissue-specific activators and inhibitors in
an evolutionally conserved manner. To understand the
mechanism of inhibition, we defined a critical role of the
P1 leucine in the reactive center loop (RCL). Further,
synthetic peptides derived from the RCL are sufficient for
the inhibitory function. The implication of a-ACT in control
proMMP-9 activation is further supported by our clinical
findings: (1) in the early stage of trauma, the absence of
proMMP-9 activation is associated with a large amount of
intact a-ACT; and (2) with the progression of wound healing,
the maturation of proMMP-9 is associated with degradation
and inactivation of a-ACT. Taken together, we demonstrated,
for the first time, to the best of our knowledge, that a-ACT is a
pathophysiologic inhibitor that controls proMMP-9 activation
in skin tissue.
RESULTS
TNF-a-induced activation of proMMP-9 in human skin is
inhibited by a-ACT but not by a-1-antitrypsin
To maximally produce mature MMP-9, the normal human
skin was costimulated by TNF-a (10 ngml1) and TGF-b
(1 ngml1). Purified a-ACT and a-1-antitrypsin (a-AT) were
added directly to the culture at the indicated concentration.
After 3 days of culture, the conditioned medium was resolved
by zymography. As shown in Figure 1a, in the absence
of cytokine treatment, the 72-kDa proMMP-2 and a minimal
amount of 92-kDa proMMP-9 were produced in the condi-
tioned medium. In response to the cytokines, 92-kDa
proMMP-9 was substantially induced and converted into
82-kDa mature form. a-ACT at 10 mgml1 totally blocked the
maturation of proMMP-9 but had no effect on the expression
of the zymogen. In contrast, a-AT was found to have no
significant effect on proMMP-9 activation, indicating the fine
specificity of the converting enzyme as chymotrypsin-like
serine proteinase. Importantly, this effective concentration of
a-ACT (0.01mgml1) is only about 1/50 of the maximal
plasma concentration in the acute response to injury
(0.5mgml1), implying the pathophysiologic relevance of
the inhibitor in restraining proMMP-9 activation (Travis et al.,
1990). To determine whether such inhibition can be
extended to other species, we stimulated the rat skin explants
with TNF-a together with a-ACT. As expected, TNF-a-
induced maturation of proMMP-9 was completely inhibited
by exogenous a-ACT (data not shown).
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Figure 1. Cytokine-induced activation of proMMP-9 in human skin is
inhibited by a-ACT but not by a-AT. Explants of full thickness normal
human skin donors were cultured in DMEM and treated with TGF-b and
TNF-a. Purified human a-ACT and a-AT were added to the skin culture at
the indicated concentration. After culture for 3 days, the conditioned
medium was resolved by gelatinolytic zymography. The identity of MMP-9
and MMP-2 has been previously confirmed by western blot.
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In vitro inhibition of proMMP-9 activation by a-ACT
a-ACT was added to the reactions containing purified
proMMP-9 and human skin extract that contained the
converting enzyme as described previously (Han et al.,
2002). As shown in Figure 2a, a-ACT at 0.5 mgml1 exhibited
partial inhibition; at 5 mgml1, the inhibitor nearly blocked
the conversion as indicated by the accumulation of proMMP-9.
The a-ACT protein was confirmed by western blot analysis
(Figure 2b). Importantly, a-ACT exerted its inhibition at
5 mgml1, which was 1% of the amount in the plasma in the
acute phase (500mgml1), suggesting a pathophysiologic
relevance of the inhibitor in acute-phase reaction by
attenuation of proMMP-9 activation.
The P1 leucine in the RCL of a-ACT is necessary for the
inhibition of proMMP-9 activation
a-ACT belongs to a family of serine protease inhibitors
called serpins and exerts its proteolytic inhibition through
a ‘‘suicide’’ mechanism by which the RCL of the inhibitor
is inserted into the catalytic domain of the proteases (Travis
et al., 1990). In this regard, we changed the critical leucine
(P1) to serine, designated P1m, and the adjacent serine (P10)
to alanine, called P10m (Figure 3a). Six histidines were added
as a tag to the C terminus of the a-ACT variants to facilitate
purification. The wild-type a-ACT and two mutant variants
were expressed by lentivirus in immortalized human kerati-
nocytes (IKCs). a-ACT variants from the conditioned medium
were purified using Ni-NTA chromatography to near
homogeneity, as shown by protein staining and western blot
(Figure 3b and c). We performed the converting assay by
incubating proMMP-9 with human skin extract and a-ACT
variants. As shown in the zymography, the wild-type a-ACT
at 50 mgml1 clearly blocked the maturation process,
whereas the leucine mutation (P1m) abolished its inhibition
(Figure 3d). In contrast, the P01 serine mutant (P10m) still
retains its inhibition, showing efficiency similar to that of the
wild type (Figures 2 and 3e). Thus, the P1 leucine in the RCL
is critical for a-ACT to inhibit proMMP-9 conversion.
The RCL of a-ACT is sufficient to inhibit proMMP-9 activation
We further addressed the question of whether the RCL of
a-ACT is sufficient to exert the inhibition of proMMP-9 acti-
vation. To this end, we synthesized a linear peptide of
25 residues corresponding to the RCL from amino-acid
residues 153 to 177 of human a-ACT (Figure 4a). A cyclic
peptide of the RCL was also created by introducing two
cysteines followed by oxidation. First, we performed an
in vitro assay by incubating the peptides or a-ACT protein
with human skin extract together with proMMP-9. Both the
linear and cyclic peptides potently inhibited the conversion
(Figure 4b). We then tested the inhibition of the RCL peptides
by organ culture of human skin. As shown in Figure 4c, the
cytokine-induced conversion of proMMP-9 in human skin
was completely inhibited by the peptides at 140 nM. As an
internal control, the expression of proMMP-2 and proMMP-9
as well as the conversion of proMMP-2 were not affected by
the peptides, which underlines the specificity of a-ACT on
proMMP-9 maturation. Thus, the RCL of a-ACT is necessary
and sufficient to attenuate conversion of proMMP-9 in human
skin.
In addition to proteolytic cleavage, latent MMPs can
also be activated by organomercurial compounds such as
4-aminophenylmercuric acetate through disruption of the
bond between the conserved cysteine in the prodomain and
the zinc atom in the catalytic domain, leading the consequent
autocleavage, a process called ‘‘cysteine switch’’ (Springman
et al., 1990). As shown in Figure 4d, 4-aminophenylmercuric
acetate (0.7mgml1) efficiently provoked maturation of
proMMP-9, converting from 92 to 82 kDa. The peptide of
the RCL had no effect on the conversion, but at the same
concentration it effectively attenuated the skin proteinase-
mediated activation of the zymogen. As expected, the
organomercurial compound–induced activation of proMMP-9,
which bypasses the initial step of proteolytic cleavage, is
refractory to the serine protease inhibitor (data not shown).
Burn blister fluid contains a large amount of a-ACT, which
prevents proMMP-9 activation
We initially speculated that the latent form of proMMP-9
observed in the acute phase of injury is due to the presence of
inhibitory components in wound fluid. To test this hypothesis,
we directly measured the possible inhibitory function
of thermal burn blister fluid. To reduce the background of
endogenous gelatinases, the thermal burn blisters were
cleaned with gelatin-conjugated Sepharose 4B. The resulting
blister fluid was added to the assay system containing
proMMP-9 and human skin extracts. As shown in Figure 5a,
the formation of a 82-kDa band was completely prevented by
the blister fluid from all three patients. We thus demonstrated
the presence of an inhibitory factor(s) in the acute phase
of injured tissues that controls the activation of proMMP-9.
We then measured the protein level of a-ACT in the burn
blister fluid by western blot analysis. As shown in Figure 5b,
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Figure 2. In vitro inhibition of proMMP-9 activation by a-ACT. To directly
assess the inhibitory function of a-ACT, the skin extract was incubated
with proMMP-9 and recombinant a-ACT. (a) After a 16-hour reaction,
the products were resolved by gelatinolytic zymography. (b) The a-ACT
protein was measured by western blot.
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Figure 3. A conserved leucine (P1) in the RCL of a-ACT is essential for inhibition of proMMP-9 activation. (a) Sequence information of the RCL of human
a-ACT indicates the P1 leucine and the variants. (b and c) The a-ACT variants were expressed by IKCs transduced by lentivirus. A polyhistidine tag was
added to the C terminus of the a-ACT variants. The a-ACT variants were purified from the conditioned medium by Ni-NTA column and examined by Coomassie
blue and western blot analysis. (d and e) Inhibition by the a-ACT variants was assayed by incubation with proMMP-9 and skin extract, and the reactions
were revealed by zymography.
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Figure 4. Synthetic peptides derived from the RCL are sufficient to inhibit proMMP-9 but not proMMP-2 activation. (a) The sequence of the peptides derived
from the RCL. (b) For in vitro inhibition, peptides or a-ACT protein were incubated with proMMP-9 and the skin extract, and reactions were resolved by
zymography. (c) Ex vivo inhibition was carried out by culture of human skin explants with TGF-b and TNF-a together with the peptides or a-ACT protein.
(d) Activation of proMMP-9 was induced by APMA, and the effect of an RCL peptide was measured in the system. APMA, 4-aminophenylmercuric acetate.
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a 65-kDa band from the burn blister was recognized by the
antibodies and comigrated with the purified human a-ACT.
Based on the standard curve of purified a-ACT, we estimated
the concentration of the inhibitor in the blister at 0.2mgml1,
which is close to the pathophysiologic level of the
acute-phase factor in plasma (0.5mgml1) and about 20
times higher than the effective concentration (0.01mgml1;
Figure 1). If a-ACT indeed prevents activation of proMMP-9
in the acute phase of injury, the MMP-9 should be in latent
form in the blister fluid. Gelatinases in the blister fluid
were pulled down by gelatin-conjugated Sepharose 4B and
resolved by zymography. As shown in Figure 5c, the majority
of MMP-9 from the patients was proMMP-9 (92 kDa) without
the mature 82-kDa active form.
The a-ACT in chronic wounds is degraded and non-functional,
which is associated with maturation of proMMP-9
If a-ACT plays a pathophysiologic role by inhibiting matura-
tion of proMMP-9 in the acute phase, as shown in Figure 5,
the activation of the zymogen observed during the progres-
sion of wound healing, on the other hand, should rely on the
breakdown or inactivation of a-ACT. To examine this notion,
we surveyed a-ACT and MMP-9 from wound tissues for such
a relationship. Biopsies from chronic wounds (more than
30 days without closure) of thermal burn patients and healed
skin were examined for gelatinases and a-ACT. As shown
in Figure 6a, no MMP-9 was found in healed skin tissue,
whereas both active and latent MMP-9 was observed in the
non-healing tissues. In contrast, proMMP-2 was constitutively
expressed by both healed and non-healing skin tissue.
Western blot analysis showed the presence of 65-kDa
a-ACT as well as the fragmented and conjugated products in
the non-healing skin tissue, which may be associated with the
inactivation of the inhibitor in human skin (Figure 6b and c).
A large-scale survey of inactivation of a-ACT in non-healing
wounds has been conducted (Reiss et al., in preparation). In
addition, we tested inactivation and fragmentation of a-ACT
by incubating the purified inhibitor with human skin explants.
Exogenous a-ACT was truncated by incubation with human
skin. Thus, the massive activation of proMMP-9 that occurs in
wounds is linked to the inactivation of a-ACT.
Cathepsin G–induced activation of proMMP-9 is inhibited
by a-ACT
To further strengthen the notion of chymotrypsin-mediated
activation of proMMP-9, we directly tested conversion of
proMMP-9 by a known chymotrypsin-like proteinase, cathe-
psin G, derived from neutrophils in secreted azurophil
granules. As shown in Figure 7a, incubation of purified
proMMP-9 with cathepsin G led the conversion of proMMP-9
into its 82-kDa form. Conversely, incubation with a-ACT
resulted in inhibition of the maturation of the zymogen. Indeed,
a-ACT at 1mgml1 showed initial inhibition, and at 10mgml1
it totally prevented the cathepsin G–mediated conversion of
proMMP-9. Such concentration of inhibition matches well with
the inhibitor against the human skin-mediated conversion of
Burn blister (5 μl)
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proMMP-9
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Figure 5. Inhibition of proMMP-9 activation by burn blister fluid is associated with a large amount of a-ACT. (a) Blister fluid from thermal burn patients
(n¼6) was incubated with proMMP-9 and skin extract. After a 16-hour incubation, the reactions were resolved by zymography. (b) The same blister fluid was
examined for a-ACT by western blot analysis. (c) Gelatinases from the blister were pulled down by gelatin-conjugated Sepharose 4B and resolved by
zymography. The proMMP-9 and MMP-9 were indicated by resolving the conditioned medium from human skin culture stimulated by TGF-b and TNF-a.
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proMMP-9, as shown in Figures 1 and 2. Further, we tested
the possible conjugation of a-ACT to the converting enzyme.
As shown, a-ACT was found to be conjugated to cathepsin G
but not to elastase (Figure 7b).
DISCUSSION
The serine proteinase inhibitors (serpins) are a superfamily
of proteins with diverse physiological functions, including
the control of blood coagulation, complement activation,
Non-healing
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Intact α-ACT
Degraded α-ACT
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proMMP-2
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Fragmentation
Hours 0 2 4 8 14 20
Skin+α-ACT
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Figure 6. Activation of proMMP-9 in non-healing wounds is associated with degradation of a-ACT. (a) The biopsies of healed and non-healing wounds (n¼ 6)
were resolved by zymography. (b and c) The presence of a-ACT in the wound fluid (n¼ 6) was examined by western blot analysis. Intact, fragmented,
and conjugated a-ACT proteins were indicated. (d) Degradation of a-ACT in human skin was assayed by incubating the recombinant protein with human
skin explants for the indicated time and then resolved by western blot analysis.
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Figure 7. A model showing proMMP-9 activation in human skin is mediated by chymotrypsin-like proteinase and inhibited by TIMP-1 and a-ACT. (a) To verify
the concept that a-ACT-exerted inhibition of proMMP-9 activation occurs via the targeting of a chymotrypsin-like enzyme in human skin, we tested a-ACT for
its inhibition of cathepsin G–mediated maturation of proMMP-9. The a-ACT was incubated with proMMP-9 together with cathepsin G, and the reaction was
resolved by zymography. (b) Conjugation of cathepsin G, but not elastase, with a-ACT was measured by western blot analysis for a-ACT. (c) A proposed
model for induction, activation, and inhibition of proMMP-9 in human skin during tissue injury and healing. Two inhibitors—TIMP-1, which binds to
proMMP-9, and a-ACT, which directly targets the converting enzyme—participate in controlling the maturation of proMMP-9. Downregulation of TIMP-1
and inactivation of a-ACT are prerequisites for conversion of proMMP-9.
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programmed cell death, development, and wound healing
(Travis et al., 1988; Baumann and Gauldie, 1994). This family
of inhibitors has a molecular weight of about 350–500 amino
acids and folds into a conserved structure that uses a unique
suicide substrate-like inhibitory mechanism. Serpins are of
pathophysiologic importance because the defective inhibitors
have been found in blood clotting disorders, emphysema,
cirrhosis, and dementia (Carrell et al., 1989; Travis et al.,
1990). In this study, we identified a previously unreported
function for a particular serpin in wound healing. Specifi-
cally, we found a biochemical function of a-ACT that
controls the proteolytic activation of proMMP-9. At the
molecular level, we demonstrated that the RCL and the P1
leucine within the loop are critical for the inhibition.
Eventually, the peptides derived from the RCL of a-ACT
are sufficient to hamper the activation of proMMP-9 in
skin. Based on the evidence of a large amount of intact a-ACT
and lack of activation of the zymogen in the acute phase,
we suggest that a-ACT is a pathophysiologic inhibitor for
proMMP-9 activation. Conversely, the loss of a-ACT during
the progression of wound healing is associated with the
proteolytic activation of proMMP-9.
In response to injury, proMMP-9 and a-ACT are expressed
almost simultaneously, and the level of acute-phase factors
including a-ACT peaks at approximately 8 hours (Batstone
et al., 1983; Salo et al., 1994; Moses et al., 1996; Tarlton
et al., 1997). Such a temporal relationship could explain the
latency of proMMP-9 found in acute wounds or after surgical
trauma. Despite such correlation, MMP-9 and a-ACT are
seemingly regulated in a different manner. MMP-9 is expres-
sed mostly by inflammatory cells as well as many stromal
cells in response to cytokine stimulation. For instance, we
noticed that both epidermal keratinocytes and dermal fibro-
blasts can express proMMP-9 in response to proinflammatory
cytokines (Han et al., 2001a). On the other hand, a-ACT
is produced mostly by hepatocytes in response to innate
immunity, including IL-6 and IL-1 stimulation (Castell et al.,
1989; Fey et al., 1989). In fact, IL-6, originally called
hepatocyte-stimulatory factor, was regarded as a major
wound signal for liver cells to secrete acute-phase factors
(Baumann et al., 1986). Thus, it is possible that wound
signals, such as extracellular calcium and ATP within the
damaged tissue, activate the keratinocytes and inflammatory
cells to release IL-6, which in turn circulates to the liver and
turns on the acute-phase response. Consequently, a large
amount of a-ACT reaches the wound bed and controls
MMP-9 activation.
On the other hand, TIMP-1 conducts its inhibition
of MMP-9 in a different manner, by direct binding to
proMMP-9, which may physically block the access of the
zymogen to converting enzymes (O’Connell et al., 1994).
Thus, we propose a model of two inhibitors—TIMP-1, which
exerts its action on proMMP-9 (at the substrate level), and
a-ACT, which directly targets the converting enzyme—to
achieve the control of proMMP-9 activation in tissue injury
(Figure 7d). Conversely, downregulation or inactivation of the
two inhibitors is a prerequisite for the conversion of proMMP-
9 in degenerative diseases, including cancer metastasis and
wound healing. Additional evidence to support this two-
inhibitor hypothesis has been provided by our previous
work, which showed that the TNF-a-exerted activation of
proMMP-9 in human skin is mediated by downregulation
of TIMP-1 (Han et al., 2002). Our results are consistent with
clinical observations that in acute wounds both TIMP-1 and
a-ACT are upregulated, in line with the latency of proMMP-9
(Batstone et al., 1983; Ladwig et al., 2002), whereas in
chronic wounds TIMP-1 was found to be downregulated
(Saarialho-Kere, 1998). In this report, we show the degrada-
tion of a-ACT in the non-healed wounds. a-ACT protein in
the wound bed is probably inactivated through proteolytic
cleavage of a-ACT, a general mechanism of clearance of
serpins (Kress, 1983; Potempa et al., 1991; Rao et al., 1995).
Proteolytic inactivation of a-ACT and a-AT by neutrophils
was observed in arthritic joints (Abbink et al., 1993). This
observation is in line with our data showing cathepsin
G–mediated activation of proMMP-9 and inhibition by a-ACT
(Figure 6). Similarly, inactivation of a-ACT in skin tissue is
likely also mediated by mast cell chymase (Schechter et al.,
1989). Despite these points, it is not known which protein-
ase(s) is involved in the inactivation of a-ACT in chronic
wounds. Thus, the inactivation of a-ACT and the activation of
proMMP-9 are tightly associated in pathologic development
in degenerative diseases. Our model may also shed light on
the observed sequential production and activation of MMP-9
with breast cancer progression (Rha et al., 1997). The findings
reported here may also be relevant to other degenerative
diseases in which there is dysregulated MMP-9 activation.
For example, it has been found that a-ACT is closely
associated with the b-amyloid deposits in the brains of
individuals with Alzheimer’s disease, implying a role for this
inhibitor in amyloid deposition (Abraham and Potter, 1989).
This suggests that a-ACT can promote the formation of the
neurotoxic amyloid deposits that are a pathologic hallmark of
the disease (Potter et al., 2001). Others have found that MMP-9
in the human hippocampus retains its latent form, whereas
active MMP-9 is capable of degrading the b-amyloid peptide
(Backstrom et al., 1996; Lim et al., 1997). Accumulation of
amyloid could be due to a lack of degradation. Thus, it is
plausible that the overdeposition of b-amyloid in Alzheimer’s
may be due, in part, to accumulation of a-ACT, which
consequently blocks maturation of proMMP-9, leading to
retarded matrix clearance.
MATERIALS AND METHODS
Materials and reagents
Cytokines were purchased from R&D Systems (Minneapolis, MN).
Antibodies to a-ACT were purchased from Neomarkers (Runcorn,
Cheshire, UK). Anti-MMP-9 (C-terminus) was from Chemicon
(Billerica, MA). The enhanced chemiluminescence and gelatin
Sepharose 4B were purchased from Amersham (Little Chalfont,
Buckinghamshire, UK). a-AT, a-ACT, and cathepsin G were
purchased from Calbiochem (Gibbstown, NJ). DNA ladders and
protein markers were supplied through the courtesy of Transgen
(Beijing, China). Peptides derived from the RCL of a-ACT were
synthesized by JPT Peptide Technologies GmbH (Volmerstrasse,
Berlin, Germany).
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Biopsies and animals
Clinical biopsies, including those of normal skin and chronic
wounds, were collected according to the protocol approved by the
Internal Review Board (IRB) at the University of Southern California,
and consent was obtained from patients. The study was performed
according to the Declaration of Helsinki Principles. The fluid that
accumulated within burn blisters was collected by sterile aspiration
within 48hours after injury and stored at 80 1C for batch analysis.
Chronic wounds were defined as those that did not close for
more than 30 days while similar wounds in the same patient had
healed. The 6-mm punch biopsies were placed in 2-ml DMEM with
antibiotics (200Uml1 penicillin G sodium, 200Uml1 strepto-
mycin sulfate, and 0.5 mgml1 amphotericin B). To accumulate
the secreted factors, the biopsies were incubated in the medium
for 6 hours with the supply of 5% CO2 at 37 1C. The conditioned
medium and blister fluid were cleared of debris by centrifugation
at 5,000 g before zymography or western blot analysis. Animal
procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Southern California. The
pieces of rat skin were cultured in DMEM with antibiotics and
cytokines for 3 days.
Organ culture and cytokine stimulation of human skin
Normal human skin was obtained, in an IRB-approved manner,
from patients undergoing reconstructive or aesthetic surgery. Fat
and connective tissue were removed. The full-thickness skin was
decontaminated by incubation in DMEM containing an antibiotic at
4 1C overnight. The skin was cut into 0.25-cm2 pieces and incubated
in DMEM at 37 1C with 5% CO2 for 8 hours. To reduce the effects of
endogenous soluble factors in the skin induced by the harvesting
process, the medium was changed three times during the 8-hour
incubation. Finally, the pieces of skin were floated in 2ml DMEM
with or without TGF-b (1 ngml1) and TNF-a (10 ngml1). For the
inhibition experiment, purified a-ACT or a-AT was added to the skin
organ culture. The cultures were maintained at 37 1C with 5% CO2.
The conditioned media were sampled at the intervals indicated in
the text for gelatinolytic zymography and western blot analysis as
mentioned below.
Plasmid construction, lentivirus, and preparation of proMMP-9
and a-ACT variants
The cDNA coding human proMMP-9 (clone ID: 4054882) was from
Open Biosystems (Huntsville, AL). The full-length cDNA was cloned
into a lentiviral vector, and a replication-defective virus was
prepared by packing in HEK 293T. IKCs were transduced by the
virus coding either MMP-9 or green fluorescent protein as a control.
Transduced IKCs were grown in keratinocyte grown medium
(Invitrogen, Carlsbad, CA), and conditioned medium was collected.
The conditioned medium was centrifuged at 4,000 g for 20minutes
and the supernatant was loaded into a gelatin-conjugated Sepharose
4B column. The column was washed with buffer containing 1%
Triton X-100 in 100mM NaCl and 50mM Tris, pH 7.5, and MMP-9
was eluted by 6M urea. The eluted MMP-9 was dialyzed by
NT buffer (100mM NaCl and 50mM Tris, pH 7.5). MMP-9 activity
was measured by zymography, identity was confirmed by western
blot analysis, purity was measured by SDS-PAGE and silver staining,
and concentration was measured by A280 absorption. Human a-ACT
cDNA in pCMV-SPORT6 was from Open Biosystems. A tag of six
histidines was added to the C terminus before the stop codon.
Two variants in the active loop of a-ACT were generated by
Quick-Change mutagenesis (Stratagene, La Jolla, CA). A conserved
leucine residue (P1) in the active loop of wild type (-ctc ctt tct gca-)
was mutated to serine (-ctc tct tct gca-), designated as P1m (Figure 3).
The adjacent serine (P10) in the active loop was changed to alanine
(-ctc tct gct gca-), designated as P10m. The three a-ACT variants were
cloned into the lentiviral vector. IKC was transduced by the
lentivirus. The a-ACT in the conditioned medium was purified by
Ni-NTA kit from Qiagen (Valencia, CA). Purified protein was
examined by western blot analysis, SDS-PAGE, and protein staining.
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